Two major strategic collaborations announced in July and August 2026 underscore the intensifying race to capture value from ...

Two biosimilars—Zimrixby (rituximab-cdxx) and Garzulys (insulin aspart-fsan)—received US Food and Drug Administration (FDA) approval in July 2026, expanding treatment options in oncology, immunology ...

Semaglutide is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. It is a peptide similar to the hormone glucagon ...

Pembrolizumab is a humanized (from mouse) monoclonal antibody that binds to, and blocks PD-1 located on lymphocytes. It is an anticancer medication used in the treatment of melanoma, lung cancer, head ...

Pertuzumab is a monoclonal antibody that inhibits the dimerization of human epidermal growth factor receptor 2 (HER2) with other HER receptors, which prevents them from signalling in ways that promote ...

Insulin aspart is a type of manufactured insulin used to treat type 1 and type 2 diabetes. It has a more rapid onset and a shorter duration of activity than normal human insulins. The originator ...

India's largest pharmaceutical acquisition strengthens Sun Pharma's global reach and positions the company among the world's leading biosimilars players. Sun Pharmaceutical Industries is advancing ...

The European Commission (EC) granted marketing authorization for eight biosimilars: Biocon’s Yesintek,Celltrion’s Avtozma, Eydenzelt, Osenvelt and Stoboclo; Samsung Bioepis’ Obodence and Xbryk, and ...

A key driver of Chinese biosimilars’ internationally is their partnerships with global pharmaceutical companies and overseas expansion. Companies such as Bio-Thera, Boan, Genor, Henlius, Innovent, and ...

On 19 June 2025, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions recommending the granting of a marketing authorization for six ...

In December 2025, the Organisation for Economic Co-operation and Development (OECD) published a working paper titled ‘Assessing the impact of promotion and advertising regulations on biosimilar uptake ...